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In this issue of Critical Care, Noveanu and colleagues [1] 
present intriguing observational data from the B-type 
natriuretic peptide for Acute Shortness of Breath Evalu-
ation (BASEL)-II-ICU study evalu  ating the association 
between beta-blocker therapy and mortality in 314 
patients. Current dogma suggests a role for beta 2 agonism 
in the management of respiratory disease, most notably 
in asthma and chronic obstructive pulmonary disease 
(COPD). Beta 2 agonism was also recently investigated in 
the intensive care unit (ICU) for acute respiratory distress 
syndrome (ARDS) [2]. In addition to broncho  dilatation 
and improvements in ventilatory mechanics, purported 
beneﬁ  cial eﬀ  ects include improved endothelial function, 
cytoprotection, an anti-inﬂ  am  matory  eﬀ  ect,  increased 
surfactant production, and increased alveolar ﬂ  uid 
clearance [3]. However, despite these potential beneﬁ  cial 
eﬀ   ects, a large randomized controlled trial (RCT) of 
nebulized salbutamol in ARDS, which has been published 
only in abstract form, was stopped early for futility. In 
addition, there is ongoing controversy over the safety of 
long-acting beta 2 agonists in the management of asthma, 
and data suggest that beta 2 agonism may increase 
cardiovascular morbidity in those with risk factors for 
cardiovascular disease [4].
Th  e BASEL-II-ICU study was a prospective random-
ized trial evaluating the eﬀ  ect of BNP-guided therapy 
versus standard care in ICU patients with acute respira-
tory failure [1]. Beta-blocker therapy instituted before or 
after ICU care was associated with improved mortality 
both in-hospital and at 1 year in multivariable analyses. 
Th   is association was demonstrated in stratiﬁ  ed analyses 
for both cardiac and non-cardiac causes of acute respira-
tory failure. Among the factors limiting the generaliza-
bility of the data were the strict exclusion criteria, and 
many conditions commonly seen in the ICU, including 
sepsis, shock, renal failure, trauma, and prior cardio-
pulmo  nary resuscitation, were excluded. Furthermore, 
only 13% of the cohort with acute respiratory failure 
received invasive mechanical ventilation, although 50% 
did receive non-invasive mechanical ventilation. It would 
also be useful to know what causes of death were 
modiﬁ   ed by beta 2 antagonism in acute respiratory 
failure. Another limitation of this observational data is 
that the models are at substantial risk of over-ﬁ  tting given 
that the authors evaluated 40 variables despite having 
only 51 in-hospital deaths [5].
Why might beta 2 agonism be ineﬀ  ective and antago-
nism be beneﬁ   cial in acute respiratory failure? First, 
many patients admitted with acute respiratory failure will 
suﬀ  er cardiac ischemia, a condition that potentially can 
be prevented with a beta-blocker [6]. Beta-receptors 
form an integral component of the sympathetic nervous 
system. Th   e three beta-receptor subtypes help coordinate 
neural, circulatory, gastro  intes  tinal, digestive, urinary, 
hematological, metabolic, and immune function during 
the ‘ﬁ  ght-or-ﬂ  ight response’ induced by periods of stress. 
Initially, beta agonism diverts energy to vital organs and 
upregulates homeo  static mechanisms such as platelet 
activation and coagu  lation; however, prolonged beta 
adrenergic activa  tion may prove detrimental. Data from 
RCTs have shown a beneﬁ  cial  eﬀ   ect of beta-blocker 
therapy in the treatment of chronic heart failure [7]. 
Obser  vational data suggest a possible beneﬁ  cial role for 
beta antagonism in trauma [8], including traumatic brain 
injury [9], and sepsis [10]. Two other studies have 
highlighted the beneﬁ  ts and risks of beta-blockers. Th  e 
Clopidogrel and Metoprolol in Myocardial Infarction 
Trial (COMMIT), an RCT of 45,852 acute myocardial 
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Post hoc analyses from the B-type natriuretic peptide 
for Acute Shortness of Breath Evaluation (BASEL)-II-ICU 
study suggest an association between beta-blocker 
usage at admission and improved mortality in patients 
treated in the intensive care unit for acute respiratory 
failure. Although this evidence is encouraging, there 
is a need for a phase 2 proof-of-concept randomized 
controlled trial of beta-blocker therapy in patients 
admitted with acute respiratory failure.
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© 2010 BioMed Central Ltdinfarction patients randomly assigned to a beta-blocker 
or placebo, surprised many clinicians when it demon-
strated no impact on 30-day mortality [11]. Th  is trial 
demonstrated less re-infarction and ventricular ﬁ  brilla-
tion with beta-blocker therapy, but these beneﬁ  cial 
eﬀ  ects were counterbalanced by an excess of death due to 
shock with beta-blocker therapy. Similarly, the Peri-
operative Ischemic Evaluation Study (POISE-1), an RCT of 
8,351 non-cardiac surgery patients randomly assigned to a 
beta-blocker or placebo, demon  strated that a peri  operative 
beta-blocker prevented perioperative myo  cardial infarc-
tion but increased the risk of death or stroke [12]. In 
POISE-1, the negative consequences of beta-blockade 
appeared to have occurred through an excess of clinically 
important hypotension. Th   is excess is similar to the excess 
of cardiogenic shock witnessed with beta-blockade in 
COMMIT. Th   ese data highlight the potential beneﬁ  ts of a 
beta-blocker but also the need to exclude patients in shock 
or at high risk of shock and to intensely monitor and 
manage hemo  dynamic instability. Reassuringly, current 
data suggest that cardio-selective beta-blockers do not 
induce respira  tory physiological impairment. In particular, 
beta-blockers are associated with improved outcomes in 
patients with COPD [13], a group theoreti  cally at high risk 
from bronchospasm with beta antago  nism.
Th   e data emerging from beta adrenergic modulation in 
respiratory failure mirror those of statins. Statins were 
initially designed as cholesterol-lowering agents to 
reduce cardiovascular risk, and their pleiotropic eﬀ  ects 
were soon realized and matched by observational data 
showing associations between statin use and improved 
outcomes in cohorts with pneumonia and lung injury. 
Because a small prospective phase 2 RCT suggested 
potential beneﬁ  t [14], statins are being investigated as a 
therapy for ARDS in at least two large RCTs in Europe 
and the US. Now, an appropriate phase 2 proof-of-
concept RCT investigating beta 2 antagonism in acute 
respiratory failure with strict eligibility criteria would be 
an appropriate approach to deﬁ   ne the role of beta-
blockers in acute respiratory failure.
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